Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO have?
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO has 11 citations in the OpenAlex counts ScholarIQ stores.
When was Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO published?
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO has 2021 year in the ScholarIQ index.
What is the open-access status of Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO?
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO has diamond oa status in the ScholarIQ index.
What is the DOI of Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO?
The DOI for Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO is on the source record.
What is the PMID of Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO?
The PMID for Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO is on the source record.
What is the OpenAlex record for Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO?
The OpenAlex for Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO is on the source record.